Cangene deal

In return for relinquishing its rights, CNJ will receive 50 percent of all Canadian royalties and profits received by Medi-Ject for hGH. Medi-Ject said it has already reached an agreement with a European partner and is close to signing a deal with a Canadian distributor of the drug. Canadian sales are scheduled to begin in 1995. ...